Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Honest & Transparent: NatureS Truth Is Committed To Delivering Wellness Products
All participants were 19 years of age or older
Wester continued, Given that the metabolic syndrome is a major driver of liver-related outcomes both in patients with MASLD and other chronic liver diseases such as alcohol-related liver disease or viral hepatitis C, there could be a similar effect of GLP1 agonists in patients with chronic liver diseases of any etiology with concomitant metabolic traits, such as type 2 diabetes. Using data from the Decoding the Epidemiology of LIVER disease Swedish cohort, researchers aimed to determine the long-term risk for major adverse liver outcomes (MALO) among patients with chronic liver disease and type 2 diabetes who either initiated (n = 1,026) or did not initiate (n = 15,633) GLP1 agonists
Visceral fat and hepatic fat accumulate and resolve through similar mechanisms
